Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-18-160824.txt : 20180511 0001193125-18-160824.hdr.sgml : 20180511 20180511160653 ACCESSION NUMBER: 0001193125-18-160824 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180511 DATE AS OF CHANGE: 20180511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 18826890 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 10-Q 1 d711808d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2018

☐	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File No. 001-31791

GALECTIN THERAPEUTICS INC.


Nevada		04-3562325
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

4960 Peachtree Industrial Blvd., Suite 240, Norcross, GA		30071
(Address of Principal Executive Offices)		(Zip Code)

(678) 620-3186

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.05 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

The number of shares outstanding of the registrant’s common stock as of May 8, 2018 was 37,740,647.

GALECTIN THERAPEUTICS INC.

INDEX TO FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2018


		PAGE
	PART I — FINANCIAL INFORMATION

ITEM 1.	Unaudited Condensed Consolidated Financial Statements
	Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017 (unaudited)		3
	Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2018 and 2017 (unaudited)		4
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017 (unaudited)		5
	Notes to Unaudited Condensed Consolidated Financial Statements		6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		11

ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk		18

ITEM 4.	Controls and Procedures		18

	PART II — OTHER INFORMATION

ITEM 1.	Legal Proceedings		19

ITEM 1A.	Risk Factors		19

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds		19

ITEM 3.	Defaults Upon Senior Securities		19

ITEM 4.	Mine Safety Disclosures		19

ITEM 5.	Other Information		19

ITEM 6.	Exhibits		19

SIGNATURES			20

GALECTIN THERAPEUTICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)


	March 31, 2018			December 31, 2017
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	3,988		$	3,053
Prepaid expenses and other current assets		685			766

Total current assets		4,673			3,819

Other		258			342

Total assets	$	4,931		$	4,161

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	1,151		$	608
Accrued expenses		1,132			2,292
Accrued dividends payable		—			68

Total current liabilities		2,283			2,968

Total liabilities		2,283			2,968

Commitments and contingencies (Note 9)
Series C super dividend convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at March 31, 2018 and December 31, 2017, redemption value: $7,957,000, liquidation value: $1,760,000 at March 31, 2018		1,723			1,723
Stockholders’ equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at March 31, 2018 and December 31, 2017, respectively		—			—
Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,377,500 issued and outstanding at March 31, 2018 and December 31, 2017, liquidation value $1,377,500 at March 31, 2018		557			557
Series B-1 12% convertible preferred stock; 900,000 shares authorized, issued and outstanding at March 31, 2018 and December 31, 2017, liquidation value $1,800,000 at March 31, 2018		1,761			1,761
Series B-2 12% convertible preferred stock; 2,100,000 shares authorized, issued and outstanding at March 31, 2018 and December 31, 2017, liquidation value $4,200,000 at March 31, 2018		3,697			3,697
Series B-3 8% convertible preferred stock; 2,508,000 shares authorized, 2,508,000 issued and outstanding at March 31, 2018 and December 31, 2017, liquidation value $2,508,000 at March 31, 2018		1,224			1,224
Common stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2018 and December 31, 2017, 37,645,971 and 35,789,388 issued and outstanding at March 31, 2018 and December 31, 2017, respectively		38			36
Additional paid-in capital		179,359			173,363
Retained deficit		(185,711	)		(181,168	)

Total stockholders’ equity(deficit)		925			(530	)

Total liabilities, redeemable convertible preferred stock and stockholders’ equity(deficit)	$	4,931		$	4,161

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)


	Three Months Ended March 31,
	2018			2017
	(in thousands, except per share data)
Operating expenses:
Research and development	$	2,298		$	3,772
General and administrative		1,880			1,174

Total operating expenses		4,178			4,946

Total operating loss		(4,178	)		(4,946	)

Other income (expense):
Interest income		4			9
Interest expense		(84	)		—

Total other income (expense)		(80	)		9

Net loss	$	(4,258	)	$	(4,937	)

Preferred stock dividends		(285	)		(272	)

Net loss applicable to common stockholders	$	(4,543	)	$	(5,209	)

Net loss per common share — basic and diluted	$	(0.12	)	$	(0.15	)
Weighted average common shares outstanding — basic and diluted		37,284			33,928

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


	Three Months Ended March 31,
	2018			2017
	(in thousands)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(4,258	)	$	(4,937	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		—			1
Stock-based compensation expense		1,187			330
Issuance of common stock for services		7			14
Non-cash interest expense		84			—
Changes in operating assets and liabilities:
Prepaid expenses and other assets		81			79
Accounts payable and accrued expenses		(617	)		650

Net cash used in operating activities		(3,516	)		(3,863	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants		4,451			2,145

Net cash provided by financing activities		4,451			2,145

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		935			(1,718	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		3,053			15,362

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	3,988		$	13,644

NONCASH FINANCING ACTIVITIES:
Payment of preferred stock dividends in common stock	$	353		$	339

See notes to unaudited condensed consolidated financial statements.

GALECTIN THERAPEUTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

Galectin Therapeutics Inc. (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease, skin diseases and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.

The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of March 31, 2018 and the results of its operations for the three months ended March 31, 2018 and 2017 and its cash flows for the three months ended March 31, 2018 and 2017. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2017 are derived from the Company’s audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2017.

The Company has operated at a loss since its inception and has had no significant revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2018, the Company had $4.0 million of unrestricted cash and cash equivalents available to fund future operations. The Company believes there is sufficient cash, including availability of the line of credit (discussed in Note 3 below), to fund currently planned operations at least through March 31, 2019. The Company’s ability to fund operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Accordingly, based on the forecasts and estimates underlying the Company’s current operating plan, the financial statements do not currently include any adjustments that might be necessary if the Company is unable to continue as a going concern.

The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011.

2. Accrued Expenses

Accrued expenses consist of the following:


	March 31, 2018		December 31, 2017
	(in thousands)
Legal and accounting fees	$	51	$	74
Accrued compensation		314		790
Accrued research and development costs and other		767		1,428

Total	$	1,132	$	2,292

3. Line of Credit

On December 19, 2017, the Company entered into a $10 million Line of Credit arrangement with Richard E. Uihlein, a director and shareholder who has an approximate 7% ownership interest in the Company on a fully-diluted basis at December 31, 2017. Borrowings may be made by the Company through December 31, 2018. Borrowings bear interest at the Applicable Federal Rate for short term loans published by the Internal Revenue Service (1.51% on December 19, 2017). All borrowings and interest are due on December 31, 2019 but may be prepaid without penalty. In connection with the Line of Credit agreement, the Company issued to Mr. Uihlein warrants to purchase 1 million shares of the Company’s common stock for $5 per share. Half of the warrants vested at closing of the Line of Credit and the other half vest ratably with borrowings under the agreement. There have been no borrowings under the Line of Credit through March 31, 2018.

The fair value of the 500,000 warrants vested at closing was $696,000 at the date of issuance based on the following assumptions: an expected life of 7 years, volatility of 98%, risk free interest rate of 2.05% and zero dividends. The fair value of the vested warrants was recorded in other current assets and other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from December 19, 2017 through December 31, 2019. Amortization for the three months ended March 31, 2018 of $84,000 was recorded as interest expense. The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through December 31, 2019.

4. Stock-Based Compensation

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:


	Three Months Ended March 31,
	2018		2017
Research and development	$	534	$	166
General and administrative		653		164

Total stock-based compensation expense	$	1,187	$	330

The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2017 through March 31, 2018:


	Shares		Weighted Average Exercise Price
Outstanding, December 31, 2017		5,155,263	$	4.11
Granted		460,000		5.87
Exercised		—		—
Options forfeited/cancelled		—		—

Outstanding, March 31, 2018		5,615,263	$	4.26

As of March 31, 2018, there was $1,972,000 of unrecognized compensation related to 951,181 unvested options, which is expected to be recognized over a weighted–average period of approximately 0.75 years. The weighted-average grant date fair value for options granted during the three months ended March 31, 2018 was $4.57. The Company granted 460,000 stock options during the three months ended March 31, 2018, of which 115,000 options vested upon grant with the remaining 345,000 options vesting over the remainder of 2018. Approximately $526,000 of non-cash, stock-based compensation expense was recorded during the three months ended March 31, 2018 related to the options granted during the quarter that vested upon the grant date.

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:


	Three Months Ended March 31,			Three Months Ended March 31,
	2018			2017
Risk-free interest rate		2.18	%		—
Expected life of the options		5 years			—
Expected volatility of the underlying stock		103	%		—
Expected dividend rate		0	%		—

5. Common Stock Warrants

The following table summarizes the common stock warrant activity from December 31, 2017 through March 31, 2018:


	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2017		13,229,778		$	3.35
Granted		163			5.23
Exercised		(1,780,478	)		2.50
Forfeited/cancelled		—			—

Outstanding, March 31, 2018		11,449,463		$	3.48

6. Fair Value of Financial Instruments

The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximate their carrying value due to their short-term nature. There were no level 2 or level 3 assets or liabilities at March 31, 2018 or December 31, 2017.

7. Loss Per Share

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:


	March 31, 2018 (shares)		March 31, 2017 (shares)
Warrants to purchase shares of common stock		11,449,463		12,249,016
Options to purchase shares of common stock		5,615,263		4,656,888
Shares of common stock issuable upon conversion of preferred stock		4,312,282		4,312,282

		21,377,008		21,218,186

8. Common Stock

2014 At Market Issuance of Common Stock

On March 30, 2014, the Company entered into an At Market Issuance Sales Agreement (the “2014 At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $30.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the 2014 At Market Agreement. In three months ended March 31, 2017, the Company issued 1,496,797 shares of common stock for net proceeds of approximately $1,945,000 under the 2014 At Market Agreement. The 2014 At Market Agreement expired in March 2017.

2017 At Market Issuance of Common Stock

On May 19, 2017, the Company entered into an At Market Issuance Sales Agreement (the “2017 At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $30.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the 2017 At Market Agreement. During the three months ended March 31, 2018, there were no issuances of common stock under the 2017 At Market Agreement.

2017 Private Placement

On February 28, 2017, the Company closed a transaction with five individual investors through a private placement of common stock and warrants. In total, the Company issued 102,368 shares of common stock for proceeds of $200,000. The Company also issued, to the five investors, warrants to purchase 76,776 shares of common stock at $5.00 per share. The warrants have an expiration date of February 28, 2024. The exercise price of each warrant is adjustable in the event of a stock split or stock combination, capital reorganization, merger or similar event. The warrants were valued at approximately $101,000 as of the date of issuance, using the closing price of $1.86, a life of 7 years, a volatility of 97% and a risk free interest rate of 1.92%. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity” the Company has determined that warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital.

Other

In 2018, the Company entered an agreement with a vendor whereby the Company will issue common stock to vendor in lieu of paying in cash in amount up to $100,000 for the year. For the three months ended March 31, 2018, the Company has issued 1,629 shares of common stock and 163 warrants to purchase shares of common stock pursuant to this agreement and the value of such shares has been recorded as research and development expense.

For the three months ended March 31, 2018, the Company has issued a total of 74,476 shares of common stock for dividends on Series A, Series B and Series C Preferred Stock.

9. Commitments and Contingencies

Shareholder Class Actions and Derivative Lawsuits

As previously reported, during August 2014, persons claiming to be Galectin shareholders filed putative shareholder derivative complaints seeking recovery on behalf of the Company against certain of the Company’s directors and officers in the United States District Court for the District of Nevada (the “Federal Action”) and in in state court in Las Vegas, Nevada (the “State Action” and, together with the Federal Action, the “Derivative Actions”). The complaints in the Derivative Actions alleged that certain current and former Galectin directors and/or officers breached fiduciary duties to the Company, committed waste of corporate assets, and/or were unjustly enriched. The complaint in the Federal Action also alleged claims under the federal securities laws. The Federal Action was dismissed with prejudice by order and judgment dated December 30, 2015. Although the plaintiffs in the Federal Action filed a notice of appeal, that appeal was subsequently dismissed. The State Action was dismissed with prejudice by order docketed on June 21, 2016. The dismissal of the State Action with prejudice was affirmed on appeal by the Nevada Supreme Court by opinion entered on April 5, 2018.

As also previously reported, in September 2016, the Board received a demand letter from one of the plaintiffs in the Federal Action requesting, among other things, that the Board investigate the conduct alleged in the complaint in the Federal Action and implement certain remedial measures purportedly designed to address the alleged conduct. Now that all of the shareholder litigation to which the subject matter of the demand letter relates has been resolved, the Board expects to complete its evaluation of the demand letter.

Other Legal Proceedings

The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable. There are no other significant pending legal proceedings except as noted above.

10. Galectin Sciences LLC

In January 2014, we created Galectin Sciences, LLC (the “LLC” or “Investee”), a collaborative joint venture co-owned by SBH Sciences, Inc. (“SBH”), to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000 cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (“IPR&D”) contributed by SBH. The estimated fair value of the IPR&D contributed by SBH, on the date of contribution, was $400,000. Initially, the Company and SBH each had a 50% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company’s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional investments in or distributions from the Investee, as well as the Company’s share of the Investee’s earnings, losses and/or changes in capital. The estimated fair value of the IPR&D contributed to the LLC was immediately expensed upon contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. Since then, the Company has contributed a total of $1,663,000, including $23,000 for the three months ended March 31, 2018, for expenses of the LLC. Since the end of 2014, SBH has contributed $123,000 for expenses in the LLC. As of March 31, 2018, the Company’s ownership percentage in the LLC was 79.8%. The Company accounts for the interest in the LLC as a consolidated, less than wholly owned subsidiary. Because the LLC’s equity is immaterial, the value of the non-controlling interest is also deemed to be immaterial.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements as defined under Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created therein for forward-looking statements. Such statements include, but are not limited to, statements concerning our anticipated operating results, research and development, clinical trials, regulatory proceedings, and financial resources, and can be identified by use of words such as, for example, “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and “would,” “should,” “could” or “may.” All statements, other than statements of historical facts, included herein that address activities, events, or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding: plans and expectations regarding clinical trials; plans and expectations regarding regulatory approvals; our strategy and expectations for clinical development and commercialization of our products; potential strategic partnerships; expectations regarding the effectiveness of our products; plans for research and development and related costs; statements about accounting assumptions and estimates; expectations regarding liquidity and the sufficiency of cash to fund currently planned operations through at least March 31, 2019; our commitments and contingencies; and our market risk exposure. Forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which Galectin Therapeutics operates, and management’s beliefs and assumptions. These statements are not guarantees of future performance and involve certain known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties are related to and include, without limitation,

•

our early stage of development,

•

we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit,

•

our dependence on additional outside capital,

•

we may be unable to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates,

•

uncertainties related to any litigation,

•

uncertainties related to our technology and clinical trials, including expected dates of availability of clinical data,

•

we may be unable to demonstrate the efficacy and safety of our developmental product candidates in human trials,

•

we may be unable to improve upon, protect and/or enforce our intellectual property,

•

we are subject to extensive and costly regulation by the U.S. Food and Drug Administration (FDA) and by foreign regulatory authorities, which must approve our product candidates in development and could restrict the sales and marketing and pricing of such products,

•

competition and stock price volatility in the biotechnology industry,

•

limited trading volume for our stock, concentration of ownership of our stock, and other risks detailed herein and from time to time in our SEC reports, and

The following discussion should be read in conjunction with the accompanying consolidated financial statements and notes thereto of Galectin Therapeutics appearing elsewhere herein.

Overview

We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectins have a demonstrated role in the pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when a program becomes advanced and requires significant additional resources.

Our lead galectin-3 inhibitor is GR-MD-02, which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. GR-MD-02 has the potential to treat many diseases due to galectin-3’s involvement in multiple key biological pathways such as immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death). Galectin Therapeutics Inc. is using this inhibitor to treat advanced liver fibrosis and liver cirrhosis in NASH (non-alcoholic steatohepatitis) patients. We have

completed two Phase 1 clinical studies, a Phase 2 clinical study in NASH patients with advanced fibrosis (NASH-FX) and a second Phase 2B clinical trial in NASH patients with well compensated cirrhosis. We announced, in December 2017 top line results from our Phase 2b study in NASH patients with cirrhosis (NASH-CX). NASH cirrhosis is a progressive disease, currently not treatable and ultimately may result in liver failure that has poor prognosis and no effective, approved medical therapies other than liver transplant. Galectin-3 expression is highly increased in the liver of patients with liver fibrosis and liver cirrhosis. We believe that our galectin-3 inhibitor, by reducing galectin-3 at the cellular level, ultimately showing a strong anti-fibrotic potential may provide a novel treatment for various forms of liver fibrosis.

We endeavor to leverage our scientific and product development expertise as well as established relationships with outside sources to achieve cost-effective and efficient drug development. These outside sources, amongst others, provide us with expertise in preclinical models, pharmaceutical development, toxicology, clinical trial operations, pharmaceutical manufacturing, sophisticated physical and chemical characterization, and commercial development. We also have established several collaborative scientific discovery programs with leading experts in carbohydrate chemistry and characterization. These discovery programs are generally aimed at the targeted development of new carbohydrate molecules that bind galectin proteins and offer alternative options to larger market segments in our primary disease indications. We also have established through Galectin Sciences LLC, a discovery program aimed at the targeted development of small molecules (generally, non-carbohydrate) that bind galectin proteins and may afford options for alternative means of drug delivery (e.g., oral) and as a result expand the potential uses of our galectin-3 inhibitor compounds. We are also pursuing a development pathway to clinical enhancement and commercialization for our lead compounds in immuno-oncology for cancer therapy and severe skin disease including moderate to severe plaque psoriasis and severe atopic dermatitis. However, our clinical development efforts are focused on both liver fibrosis and fatty liver disease as represented by a Phase 2 clinical trial in NASH-cirrhosis which reported top line data in December 2017. All of our proposed products are presently in development, including pre-clinical and clinical trials.

Our Drug Development Programs

Galectins are a class of proteins that are made by many cells in the body, but predominantly in cells of the immune system. As a group, these proteins are able to bind to sugar molecules that are part of other proteins, glycoproteins, in and on the cells of our body. Galectin proteins act as a kind of molecular glue, bringing together molecules that have sugars on them. Galectin proteins, in particular galectin-3, are known to be markedly increased in a number of important diseases including inflammatory diseases, scarring of organs (e.g. liver, lung, kidney, and heart) and cancers of many kinds. The increase in galectin protein promotes the disease and is detrimental to the patient. Published data substantiating the importance of galectin-3 in the fibrotic process arises from gene knockout experiments in animal studies. Mice genetically altered to eliminate the galectin-3 gene, and thus unable to produce galectin-3, are incapable of developing liver fibrosis in response to toxic insult to the liver and in fatty liver disease as well as development of fibrosis in other tissues.

We have one new proprietary chemical entity (NCE) in development, GR-MD-02, which has shown promise in preclinical and early clinical studies in treatment of fibrosis, severe skin disease, and in cancer therapy. Currently we are focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH) and more specifically in NASH cirrhosis. We have also leveraged our relationships with well-known investigators to demonstrate clinical effects of GR-MD-02 in treating moderate to severe plaque psoriasis, severe atopic dermatitis, and in cancer therapy in combination with immune-system modifying agent(s). GR-MD-02 is a proprietary, patented compound derived from natural, readily available, plant-based starting materials, which, following chemical processing, exhibits the properties of binding to and inhibiting galectin-3 proteins. A second NCE, GM-CT-01 is a proprietary, patented compound that is made from a completely different starting source plant material and also binds and inhibits galectin proteins.

Our product pipeline is shown below:


Indication	Drug	Status
Fibrosis
NASH with Advanced Fibrosis: NASH-CX trial and NASH-FX trial	GR-MD-02	IND submitted January 2013. Results from the Phase 1 clinical trial were reported in 2014, with final results reported in January 2015. End of Phase 1 meeting held with FDA in 2014. Two Phase 2 clinical trials were designed. The NASH FX trial was designed for patients with advanced fibrosis but not cirrhosis. The NASH FX trial top line data was reported in September 2016 The NASH CX trial, was designed for patients with well compensated cirrhosis. The NASH CX trial top line data was reported in December 2017 and additional results derived from the study were presented subsequently.


Indication	Drug	Status
Lung Fibrosis	GR-MD-02	In pre-clinical development
Kidney Fibrosis	GR-MD-02	In pre-clinical development
Cardiac and Vascular Fibrosis	GR-MD-02	In pre-clinical development
	GM-CT-01	Not in active development
Cancer Immunotherapy
Melanoma, Head, Neck Squamous Cell Carcinoma (HNSCC)	GR-MD-02	Investigator IND submitted in December 2013. Phase 1B study in process. A second Phase 1B study began in Q-1 2016. Investigator IND for that study submitted in September 2015. Early data was reported in February 2017 and studies with the 3^rd cohort are ongoing.
Psoriasis
Moderate to Severe Plaque Psoriasis Severe Atopic Dermatitis	GR-MD-02	IND submitted March 2015. A phase 2a trial in moderate to severe plaque psoriasis patients began in January 2016. Interim data on the first four patients were positive and were reported in May 2016. Further positive data was reported in September 2016. Investigator initiated IND submitted for treatment of three patients with severe atopic dermatitis, with positive preliminary data presented in February 2017.

Fibrosis. GR-MD-02 is our lead product candidate for treatment of fibrotic disease. Our preclinical data show that GR-MD-02 has a significant therapeutic effect on liver fibrosis as shown in several relevant animal models. In addition, in NASH animal models, GR-MD-02 has been shown to reduce liver fat, inflammation, and ballooning degeneration or death of liver cells. Therefore, we chose GR-MD-02 as the lead candidate in a development program targeted initially at fibrotic liver disease associated with non-alcoholic steatohepatitis (NASH, or fatty liver disease). In January 2013, an Investigational New Drug (“IND”) was submitted to the U.S. Food and Drug Administration (“FDA”) with the goal of initiating a Phase 1 study in patients with NASH and advanced liver fibrosis to evaluate the human safety of GR-MD-02 and pharmacodynamics biomarkers of disease. On March 1, 2013, the FDA indicated we could proceed with a US Phase 1 clinical trial for GR-MD-02 with a development program aimed at obtaining support for a proposed indication of GR-MD-02 for treatment of NASH with advanced fibrosis. The Phase 1 trial was completed and demonstrated that GR-MD-02 up to 8 mg/kg, i.v. was safe and well tolerated. The human pharmacokinetic data defined a drug dose for use in the planned Phase 2 trials based on extrapolation from efficacy data in NASH animal models of liver fibrosis and/or cirrhosis. Additionally, there was evidence of a pharmacodynamic effect of GR-MD-02 at the 8 mg/kg dose with a decrease in alpha 2 macroglobulin, a serum marker of fibrotic activity, and a reduction in liver stiffness as determined by FibroScan^®. An “End of Phase 1 Meeting” was held with FDA which, amongst other items, provided guidance on the primary endpoint for the Phase 2 clinical trial, the NASH-CX trial.

Additionally, an open label drug-drug interaction study was completed in healthy volunteers during the second quarter of 2015 with GR-MD-02, and it showed that with 8 mg/kg dose of GR-MD-02 and 2 mg/kg dose of midazolam there was no drug-drug interaction and no serious adverse events or drug-related adverse events were observed. This study was required by the FDA, and the primary objective was to determine if single or multiple intravenous (IV) doses of GR-MD-02 affect the pharmacokinetics (PK) of midazolam. The secondary objective was to assess the safety and tolerability of GR-MD-02 when administered concomitantly with midazolam. The lack of a drug interaction in this study enabled the Company to expand the number of patients eligible for its Phase 2 clinical trial. In addition, should GR-MD-02 be approved for marketing, the success of this study supports a broader patient population for the drug label.

Our Phase 2 program in fibrotic disease consists of two separate human clinical trials. The primary clinical trial is the Phase 2b NASH-CX study for one year for patients with NASH with well compensated cirrhosis, which began enrolling in June, 2015. This study is the primary focus of our program and is a randomized, placebo-controlled, double-blind, parallel-group Phase 2b trial to evaluate the safety and efficacy of GR-MD-02 for treatment of liver fibrosis and resultant portal hypertension in NASH patients with well compensated cirrhosis. A smaller, exploratory NASH-FX trial was conducted to explore potential use of various non-invasive imaging techniques in NASH patients with advanced fibrosis but not cirrhosis.

NASH-FX Trial: The NASH-FX trial, a Phase 2a pilot trial NASH-FX for patients with NASH advanced fibrosis that explored use of three non-invasive imaging technologies, is now complete. It was a short, single site, four-month trial in 30 NASH patients with advanced fibrosis, but not cirrhosis, randomized 1:1 to either 9 bi-weekly doses of 8 mg/kg of GR-MD-02 or placebo. The trial did not meet its primary biomarker endpoint as measured using multi-parametric magnetic resonance imaging (LiverMultiScan^(R), Perspectum Diagnostics). The trial also did not meet secondary endpoints that measure liver stiffness as a surrogate for fibrosis using, magnetic resonance-elastography and FibroScan^® score. We, and many experts in the field, now believe that a four-month treatment period may not be sufficient to show efficacy results in established liver fibrosis. This small study was not powered for the secondary endpoints and thus, not surprisingly did not meet the secondary endpoints. In the trial, GR-MD-02 was found to be safe and well tolerated among the patient population with no serious adverse events. Although there was no apparent improvement in the three non-invasive

tests for assessment of liver fibrosis in the four-month NASH-FX trial, the principal investigator of the NASH-FX trial has stated that the inhibition of galectin-3 with GR-MD-02 remains promising for the treatment of NASH fibrosis. Of note is that GR-MD-02 has demonstrated an improved clinical effect in moderate-to-severe psoriasis, suggesting the compound has activity in humans in an immune-mediated inflammatory human disease that can occur in association with NASH. We believe our drug candidate provides a promising new approach for the therapy of fibrotic diseases, and liver fibrosis in particular. Fibrosis is the formation of excess connective tissue (collagen and other proteins plus cellular elements such as myofibroblasts) in response to damage, inflammation or repair. When the fibrotic tissue becomes confluent, it obliterates the cellular architecture, leading to scarring and dysfunction of the underlying organ. Given galectin-3’s broad biological functionality, it has been demonstrated to be involved in cancer, inflammation and fibrosis, heart disease, and renal disease. We have further demonstrated the broad applicability of the actions of our galectin-3 inhibitor’s biological effect in ameliorating fibrosis involving lung, kidney, blood vessels, and cardiac tissues in a wide variety of animal models.

NASH-CX Trial: The NASH-CX trial was a larger well-designed multi-center clinical trial which explored use of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with well-compensated NASH cirrhosis. Enrollment in this trial was completed in September, 2016, and a total of 162 patients at 36 sites in the United States were randomized to receive either 2 mg/kg of GR-MD-02, 8 mg/kg of GR-MD-02 or placebo, with approximately 54 patients in each group. The primary endpoint is a reduction in change in hepatic venous pressure gradient (HVPG). Patients received an infusion every other week for one year, total of 26 infusions, and were evaluated to determine the change in HVPG as compared with placebo. HVPG was also correlated with secondary endpoints of fibrosis on liver biopsy as well as with measurement of liver stiffness (FibroScan^(R)) and assessment of liver metabolism (¹³C-methacetin breath test, Exalenz), which are non-invasive measures of the liver that may be used in future studies. Top line data readout was reported in December 2017 demonstrating positive efficacy data and safety and clinically meaningful results in the NASH patients with well compensated cirrhosis without esophageal varices (stage 1 cirrhosis).

In the total patient population, the primary endpoint HVPG showed a trend toward benefit with GR-MD-02 treatment, but the difference from placebo was not statistically significant. The mean change in HVPG of placebo from baseline to week 54 was 0.3 mm Hg. The mean change in HVPG from baseline was -0.37 and -0.42 for the 2 mg/kg dose and 8 mg/kg dose of GR-MD-02, respectively.

Further analysis showed that the drug effect was significantly dependent on dose “varices” in the total group of patients (p<0.02). In those NASH cirrhosis patients without varices at baseline (about 50% of the total population), there was a statistically significant effect of the 2 mg/kg dose of GR-MD-02 on the absolute change in HVPG (-1.08 mm Hg, p<0.01). The effect of the 8 mg/Kg dose of GR-MD-02 on absolute or percent change in HVPG from baseline to week 54 was not significant. The population of patients without varices at baseline were further subdivided into those with mild portal hypertension (HVPG greater or equal to 6 mm Hg and less than 10 mm Hg). In patients with mild portal hypertension (MPH), both doses of GR-MD-02 demonstrated a statistically significant effect on change in HVPG. The mean change in HVPG in the MPH group were +1.8 mm Hg for placebo and -0.3 and -0.4 mm Hg in the 2 mg/kg and 8 mg/kg dose groups, respectively. In patients with clinically significant portal hypertension (HVPG greater than 10 Mm Hg) with no varices at baseline, there was a statistically significant effect of 2 mg/kg of GR-MD-02 on the change in HVPG.

A responder analysis was performed on those patients without varices at baseline. Analysis was performed looking at two groups: those with an equal to or greater than 2 mm Hg decrease in HVPG from baseline or those with an equal to or greater than 2 mm Hg and greater than or equal to 20% decrease in HVPG from baseline. In both cases, the change observed in the GR-MD-02 2 mg/kg group was statistically significant (p<0.01) while that of the 8 mg/kg group was not.

Additional ad hoc analysis examining the pK-PD correlation between human data and the mouse NASH model showed that the apparent lack of a dose response in the 8 mg/Kg dose group (GR8) may be due to fact that a large number of patients in the GR8 group had very high levels of GR-MD-02. When the GR8 group patients were divided into groups with serum drug levels greater than 12,000 ug*hr/mL and those below 12,000 ug*hr/mL, there was a statistically significant difference in the change in HVPG in the GR8 group with lower serum levels of GR-MD-02 of approximately -8%. Thus, the apparent less pronounced effects of GR8 may be explained, at least in part, by the variable pharmacokinetics observed in the patients which received GR8. This mirrors the effects seen in the NASH mouse model experiments in which the anti-inflammatory effects of GR-MD-02 were significantly reduced at doses between 60 mg/Kg and 120 mg/Kg.

In terms of cirrhosis complications over the 54-week treatment period, in patients without varices there were statistically significantly fewer new varices that developed in the treatment groups vs placebo. We believe this may represent a useful measure of clinical outcome.

The major conclusions, to date from the NASH-CX trial results are that: i) GR-MD-02 had a statistically significant and clinically meaningful effect in improving HVPG vs placebo in patients with NASH cirrhosis who did not have esophageal varices at baseline; this effect was seen regardless of the patient’s baseline portal hypertension. Furthermore, we believe that patients with

esophageal varices may have masked benefits in the total patient population; ii) there was an important drug effect of GR-MD-02 in the total patient population on liver biopsy with a statistically significant improvement in hepatocyte ballooning (ie cell death); (iii) there was a statistically significant reduction (p=0.02) in the development of new esophageal varices in drug-treated patients compared to placebo; we believe that this is a clinically relevant endpoint related to patient outcomes; (iv) while there was a drug effect in both the 2 mg/kg and 8 mg/kg dosage groups on liver biopsy and in the mild portal hypertension group, there was a consistently greater and statistically significant effect of the 2 mg/kg dose of GR-MD-02; (v) the apparent lack of a dose response in the GR8 group may be explained by variable pharmacokinetics in the high dose group, and this suggests use of an additional and intermediate dose between 2 and 8 mg/Kg in subsequent trials; (vi) GR-MD-02 appears to be safe and well tolerated in this one year clinical trial; and (vii) we believe this is the first large, randomized clinical trial of any drug to demonstrate a clinically meaningful improvement in portal hypertension or liver biopsy in patients with compensated NASH cirrhosis without esophageal varices.

We are planning to meet with the FDA in May of 2018 to discuss the results of the NASH-CX trial and plans for a phase 3 program. Further information and details on the NASH-CX results summarized above is available in public presentations posted to our website and filed with the SEC.

The focus and goal of the therapeutic program is to stop the progression of and reverse the fibrosis in the liver and, thereby improve liver function and prevent the development of complications of fibrosis/cirrhosis and liver-related mortality in patients. The results of the NASH-CX trial substantiate that, subject to confirmation in later stage clinical trials, this goal is achievable in a significant portion of the NASH cirrhosis patient population i.e. those NASH cirrhosis patients without esophageal varices.

Cancer Immunotherapy. We believe there is potential for galectin inhibition to play a key role in the burgeoning area of cancer immunotherapy. For example, there have been several recent approvals of drugs that enhance a patient’s immune system to fight cancer. It is our goal to use a galectin inhibitor to enhance the immune system function to fight cancer in a way that complements other approaches to this type of therapy. This hypothesis is supported by the fact that galectin-3 is expressed at high levels in multiple types of tumors, adds to the malignant nature of the tumors, and protects the tumors from immune system attack. Our drug candidates provide a promising new therapeutic approach to enhance the activity of the immune system against cancer cells. Preclinical studies have indicated that GR-MD-02 enhances the immune response to cancer cells, increased tumor shrinkage and enhanced survival in immune competent mice with prostate, breast, melanoma and sarcoma cancers when combined with one of the immune checkpoint inhibitors, anti-CTLA-4 or anti-PD-1, and with the immune cell activator anti-OX40. These preclinical data led to the filing of two Investigator-sponsored INDs and the initiation of studies of GR-MD-02 in combination with Yervoy^® (ipilimumab) and KEYTRUDA (pembrolizumab) in Phase 1B studies of patients with metastatic melanoma. The KEYTRUDA trial has also been expanded to include patients with non-small cell lung cancer and head and neck squamous cell carcinoma. These studies are being conducted under the sponsorship of Providence Portland Medical Center’s Earle A. Chiles Research Institute (EACRI).

Data on this combination immunotherapy program was presented on February 7, 2017 at the 9th GTCBio Immunotherapeutics & Immunomonitoring Conference in San Diego, CA by Dr. William L. Redmond, Providence Cancer Center. Preclinical results in mouse models of multiple types of cancers showed important anti-tumor and increased survival effects of combining GR-MD-02 with different types of immune modulators, providing a case for progressing studies into human patients with cancer. Seven patients were treated in the GR-MD-02 in combination with Yervoy trial, with no safety concerns in these low dose cohorts. Due to changes in the standard of care for metastatic melanoma (i.e., approval of anti-PD-1), recruitment has been slowed significantly in this trial. Promising results were reported in the Phase 1b trial combining GR-MD-02 with pembrolizumab (KEYTRUDA). Cohort 1 was completed (n=6, 5 with melanoma, one head and neck) with one partial response and one mixed response in 5 melanoma patients. There was a rapid and marked tumor response after 3 doses of combined GR-MD-02 and pembrolizumab in the one partial response patient who had failed high-dose IL-2 and oncolytic virus + ipilimumab. The study is ongoing and progression to further development will be based on response rate as compared to historical response rates to pembrolizumab alone. Results from third cohort of patients is expected in Summer, 2018.

Severe skin diseases. During our Phase 1 NASH fibrosis trial with GR-MD-02, a clinical effect on plaque psoriasis was observed in a NASH patient who also had this disease. This patient had marked improvement in her psoriasis, with improvement beginning after the third infusion. She reported that her psoriasis was “completely gone” and her skin was “normal” after the fourth infusion. Her skin remained normal for 17 months after the final infusion of study drug. The patient is convinced that the improvement in her psoriasis is related to the study drug.

This serendipitous finding, combined with galectin-3 protein being markedly upregulated in the capillary epithelia (small blood vessels) of the psoriatic dermis (plaque lesions), led to a phase 2a trial in patients with moderate to severe plaque psoriasis. GR-MD-02 inhibition of galectin-3 may attenuate capillary changes in the psoriatic dermis and inflammatory recruitment, perhaps explaining the improvements observed in the NASH fibrosis trial patient. In this open-label, unblinded trial (no placebo, all patients knowingly receive active drug), 5 patients with moderate to severe plaque psoriasis were administered GR-MD-02 every two weeks for 24 weeks. In May 2016, we reported positive results on the first four patients after 12 weeks of therapy. Based on these results, we modified the trial to include 24 weeks of therapy. In August 2016, we reported on four patients after 24 weeks of therapy and one patient after

12 weeks of therapy. The four patients who received 24 weeks of therapy experienced an average of 48% improvement in their plaque psoriasis. At this time, the average response in all five patients remains at 50% with one patient having an 82% improvement. However, there are existing drugs on the market in this disease that produce 75% and higher improvements in 60-90% of patients. While we are encouraged that this study has demonstrated clinically meaningful results in a human disease with GR-MD-02, the next steps would entail a controlled, does-ranging clinical trial which we do not expect to conduct absent a strategic partnership.

We believe the mechanism of action for GR-MD-02 is based upon interaction with, and inhibition of, galectin proteins, particularly galectin-3, which are expressed at high levels in certain pathological states including inflammation, fibrosis and cancer. While GR-MD-02 is capable of binding to multiple galectin proteins, we believe that it has the greatest affinity for galectin-3, the most prominent galectin implicated in pathological processes. Blocking galectin in cancer and liver fibrosis has specific salutary effects on the disease process, as discussed below.

Results of Operations

Three Months Ended March 31, 2018 Compared to Three Months Ended March 31, 2017

Research and Development Expense.


	Three Months Ended March 31,				2018 as Compared to 2017 Three Months
	2018		2017		$ Change			% Change
	(In thousands, except %)
Research and development	$	2,298	$	3,772	$	(1,474	)		(39	)%

We generally categorize research and development expenses as either direct external expenses, comprised of amounts paid to third party vendors for services, or all other research and development expenses, comprised of employee payroll and general overhead allocable to research and development. We consider a clinical program to have begun upon acceptance by the FDA, or similar agency outside of the United States, to commence a clinical trial in humans, at which time we begin tracking expenditures by the product candidate. Clinical program expenses comprise payments to vendors related to preparation for, and conduct of, all phases of the clinical trial, including costs for drug manufacture, patient dosing and monitoring, data collection and management, oversight of the trials and reports of results. Pre-clinical expenses comprise all research and development amounts incurred before human trials begin, including payments to vendors for services related to product experiments and discovery, toxicology, pharmacology, metabolism and efficacy studies, as well as manufacturing process development for a drug candidate.

Our research and development expenses were as follows:


	Three Months Ended March 31,
	2018		2017
	(in thousands)
Direct external expenses:
Clinical activities	$	1,287	$	3,162
Pre-clinical activities		66		32
All other research and development expenses		945		578

	$	2,298	$	3,772

Clinical programs expenses decreased primarily due to costs related to our Phase 2 clinical trials winding down during the three months ended March 31, 2018 as compared to the same period in 2017. Other research and development expense increased primarily due to an increase in non-cash stock-based compensation expense of approximately $368,000.

Both the time required and costs we may incur in order to commercialize a drug candidate that would result in material net cash inflow are subject to numerous variables, and therefore we are unable at this stage of our development to forecast useful estimates. Variables that make estimates difficult include the number of clinical trials we may undertake, the number of patients needed to participate in the clinical trial, patient recruitment uncertainties, trial results as to the safety and efficacy of our product, and uncertainties as to the regulatory agency response to our trial data prior to receipt of marketing approval. Moreover, the FDA or other regulatory agencies may suspend clinical trials if we or an agency believes patients in the trial are subject to unacceptable risks or find deficiencies in the conduct of the clinical trial. Delays or rejections may also occur if governmental regulation or policy changes during our clinical trials or in the course of review of our clinical data. Due to these uncertainties, accurate and meaningful estimates of the ultimate cost to bring a product to market, the timing of costs and completion of our program and the period during which material net cash inflows will commence are unavailable at this time.

General and Administrative Expense.


	Three Months Ended March 31,				2018 as Compared to 2017 Three Months
	2018		2017		$ Change		% Change
	(In thousands, except %)
General and administrative	$	1,880	$	1,174	$	706		60	%

General and administrative expenses consist primarily of salaries including stock-based compensation, legal and accounting fees, insurance, investor relations, business development and other office related expenses. The primary reasons for the increase in general and administrative expenses for the three-months ended March 31, 2018 as compared to the same period in 2017 is due to an increase non-cash, stock-based compensation expense of $489,000 and as increase in business development/investor relations expenses of approximately $131,000.

Liquidity and Capital Resources

Since our inception on July 10, 2000, we have financed our operations from proceeds of public and private offerings of debt and equity. As of March 31, 2018, we raised a net total of $136.5 million from these offerings. We have operated at a loss since our inception and have had no significant revenues. We anticipate that losses will continue for the foreseeable future. At March 31, 2018, the Company had $4.0 million of unrestricted cash and cash equivalents available to fund future operations. The Company believes there is sufficient cash, including availability of the line of credit, to fund currently planned operations at least through March 31, 2019. Our ability to fund operations after our current cash resources are exhausted depends on our ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Accordingly, based on the forecasts and estimates underlying our current operating plan, the financial statements do not currently include any adjustments that might be necessary if we are unable to continue as a going concern.

Net cash used in operations decreased by $347,000 to $3,516,000 for the three months ended March 31, 2018, as compared to $3,863,000 for the three months ended March 31, 2017. Cash operating expenses decreased principally due to the winding down of Phase 2 research and development activities related to our clinical trial activity with GR-MD-02.

Net cash provided by financing activities the three months ended March 31, 2018, of $4,451,000 represents proceeds from the exercise of common stock warrants. Net cash provided by financing activities the three months ended March 31, 2017, of $2,145,000 represents net proceeds from the sale of common stock and warrants.

Other.

We have engaged outside vendors for certain services associated with our clinical trials. These services are generally available from several providers and, accordingly, our arrangements are typically cancellable on 30 days notice.

Off-Balance Sheet Arrangements

We have not created, and are not a party to, any special-purpose or off-balance sheet entities for the purpose of raising capital, incurring debt or operating parts of our business that are not consolidated into our financial statements. We do not have any arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability of capital resources.

Application of Critical Accounting Policies and Estimates

The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangible assets, accrued expenses, stock-based compensation, contingencies and litigation. We base our estimates on historical experience, terms of existing contracts, our observance of trends in the industry, information available from other outside sources and on various other factors that we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are those policies that affect our more significant judgments and estimates used in preparation of our consolidated financial statements. We believe our critical accounting policies include our policies regarding stock-based compensation, accrued expenses and income taxes. For a more detailed discussion of our critical accounting policies, please refer to our 2017 Annual Report on Form 10-K.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Market risk represents the risk of loss that may impact our financial position, operating results or cash flows due to changes in the U.S. interest rates. The primary objective of our investment activities is to preserve cash until it is required to fund operations. To minimize risk, we maintain our portfolio of cash and cash equivalents in operating bank accounts and money market funds. Since our investments are short-term in duration, we believe that we are not subject to any material market risk exposure.

Item 4. Controls and Procedures

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934) and concluded that, as of March 31, 2018, our disclosure controls and procedures were effective at a reasonable assurance level. During the quarter ended March 31, 2018, no change in our internal control over financial reporting has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

None except as discussed in Note 9 to our condensed consolidated financial statements included in this report.

Item 1A. Risk Factors

The information set forth in this report should be read in conjunction with the risk factors set forth in Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2017, which could materially impact our business, financial condition or future results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not Applicable

Item 5. Other Information

Not Applicable

Item 6. Exhibits


Exhibit Number	Description of Document	Note Reference

31.1*	Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

31.2*	Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

32.1**	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS	XBRL Instance Document*

101.SCH	XBRL Taxonomy Extension Schema Document*

101.CAL	XBRL Taxonomy Calculation Linkbase Document*

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB	XBRL Taxonomy Label Linkbase Document*

101.PRE	XBRL Taxonomy Presentation Linkbase Document*

*	Filed herewith.

**	Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 11, 2018.


GALECTIN THERAPEUTICS INC.
By:		/s/ Peter G. Traber
Name:		Peter G. Traber, M.D.
Title:		Chief Executive Officer and President (principal executive officer)
		/s/ Jack W. Callicutt
Name:		Jack W. Callicutt
Title:		Chief Financial Officer (principal financial and accounting officer)

EX-31.1 2 d711808dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

I, Peter G. Traber, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Galectin Therapeutics Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d711808dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

I, Jack W. Callicutt, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Galectin Therapeutics Inc;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d711808dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter G. Traber, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Galectin Therapeutics Inc. and will be retained by Galectin Therapeutics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 d711808dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack W. Callicutt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.INS 6 galt-20180331.xml XBRL INSTANCE DOCUMENT 400000

0.500

5.00

1.86

0.030 30000000

0.0151

10000000

37740647 0.030 30000000

13644000

50000000

37645971

951181

500000

0.001

37645971

5615263

4.26

-185711000

2283000

4931000

314000

1151000

925000

38000

179359000

51000

2283000

1132000

4673000

3988000

1972000

4931000

258000

685000

20000000 20000000 0.01 0

1000000

1629

100000

0.798

176

1000

1723000

1760000

7957000

2508000

1224000

2508000

1377500

1742500

557000

1377500

900000

1761000

1800000

2100000

3697000

4200000

11449463

3.48

15362000

50000000

35789388

0.001

35789388

5155263

4.11

-181168000

2968000

4161000

790000

608000

-530000

68000

36000

173363000

74000

2968000

2292000

3819000

3053000

4161000

342000

766000

20000000 20000000 0.01 0

176

1000

1723000

2508000

1224000

1377500

1742500

557000

900000

1761000

2100000

3697000

13229778

3.35

0.07

0.97

0.0192

P7Y

102368

101000

200000

76776

123000

1663000

400000

1428000

21218186

-3863000

33928000

-0.15

-4946000

-4937000

9000

-5209000

-79000

1000

14000

272000

2145000

330000

1174000

2145000

3772000

-1718000

650000

4946000

339000

1496797

1945000

4312282

4656888

12249016

164000

166000

<div> 2. Accrued Expenses Accrued expenses consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Legal and accounting fees </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued compensation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">314</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">790</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued research and development costs and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">767</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,428</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,132</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,292</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

21377008

<div> 9. Commitments and Contingencies Shareholder Class Actions and Derivative Lawsuits As previously reported, during August 2014, persons claiming to be Galectin shareholders filed putative shareholder derivative complaints seeking recovery on behalf of the Company against certain of the Company’s directors and officers in the United States District Court for the District of Nevada (the “Federal Action”) and in in state court in Las Vegas, Nevada (the “State Action” and, together with the Federal Action, the “Derivative Actions”). The complaints in the Derivative Actions alleged that certain current and former Galectin directors and/or officers breached fiduciary duties to the Company, committed waste of corporate assets, and/or were unjustly enriched. The complaint in the Federal Action also alleged claims under the federal securities laws. The Federal Action was dismissed with prejudice by order and judgment dated December 30, 2015. Although the plaintiffs in the Federal Action filed a notice of appeal, that appeal was subsequently dismissed. The State Action was dismissed with prejudice by order docketed on June 21, 2016. The dismissal of the State Action with prejudice was affirmed on appeal by the Nevada Supreme Court by opinion entered on April 5, 2018. As also previously reported, in September 2016, the Board received a demand letter from one of the plaintiffs in the Federal Action requesting, among other things, that the Board investigate the conduct alleged in the complaint in the Federal Action and implement certain remedial measures purportedly designed to address the alleged conduct. Now that all of the shareholder litigation to which the subject matter of the demand letter relates has been resolved, the Board expects to complete its evaluation of the demand letter.   Other Legal Proceedings The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable. There are no other significant pending legal proceedings except as noted above. </div>

<div> 4. Stock-Based Compensation Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">534</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">166</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">653</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">164</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,187</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">330</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2017 through March 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,155,263</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.11</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">460,000</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.87</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Options forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,615,263</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> As of March 31, 2018, there was $1,972,000 of unrecognized compensation related to 951,181 unvested options, which is expected to be recognized over a weighted–average period of approximately 0.75 years. The weighted-average grant date fair value for options granted during the three months ended March 31, 2018 was $4.57. The Company granted 460,000 stock options during the three months ended March 31, 2018, of which 115,000 options vested upon grant with the remaining 345,000 options vesting over the remainder of 2018. Approximately $526,000 of non-cash, stock-based compensation expense was recorded during the three months ended March 31, 2018 related to the options granted during the quarter that vested upon the grant date. The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.18</td> <td valign="bottom" nowrap="nowrap">%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected life of the options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5 years</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility of the underlying stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">103</td> <td valign="bottom" nowrap="nowrap">%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected dividend rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

Q1 2018 10-Q 0001133416

<div> 10. Galectin Sciences LLC In January 2014, we created Galectin Sciences, LLC (the “LLC” or “Investee”), a collaborative joint venture co-owned by SBH Sciences, Inc. (“SBH”), to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000 cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (“IPR&D”) contributed by SBH. The estimated fair value of the IPR&D contributed by SBH, on the date of contribution, was $400,000. Initially, the Company and SBH each had a 50% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company’s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional investments in or distributions from the Investee, as well as the Company’s share of the Investee’s earnings, losses and/or changes in capital. The estimated fair value of the IPR&D contributed to the LLC was immediately expensed upon contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. Since then, the Company has contributed a total of $1,663,000, including $23,000 for the three months ended March 31, 2018, for expenses of the LLC. Since the end of 2014, SBH has contributed $123,000 for expenses in the LLC. As of March 31, 2018, the Company’s ownership percentage in the LLC was 79.8%. The Company accounts for the interest in the LLC as a consolidated, less than wholly owned subsidiary. Because the LLC’s equity is immaterial, the value of the non-controlling interest is also deemed to be immaterial. </div>

-3516000

<div> Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018 (shares)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017 (shares)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Warrants to purchase shares of common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,449,463</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,249,016</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Options to purchase shares of common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,615,263</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,656,888</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Shares of common stock issuable upon conversion of preferred stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,312,282</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,312,282</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,377,008</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,218,186</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P5Y

GALT false

<div> Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">534</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">166</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">653</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">164</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,187</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">330</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

5.87

0.00

0.0218

4.57

37284000

<div> 1. Basis of Presentation Galectin Therapeutics Inc. (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease, skin diseases and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions. The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of March 31, 2018 and the results of its operations for the three months ended March 31, 2018 and 2017 and its cash flows for the three months ended March 31, 2018 and 2017. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2017 are derived from the Company’s audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2017. The Company has operated at a loss since its inception and has had no significant revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2018, the Company had $4.0 million of unrestricted cash and cash equivalents available to fund future operations. The Company believes there is sufficient cash, including availability of the line of credit (discussed in Note 3 below), to fund currently planned operations at least through March 31, 2019. The Company’s ability to fund operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Accordingly, based on the forecasts and estimates underlying the Company’s current operating plan, the financial statements do not currently include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011. </div>

--12-31

<div> 3. Line of Credit On December 19, 2017, the Company entered into a $10 million Line of Credit arrangement with Richard E. Uihlein, a director and shareholder who has an approximate 7% ownership interest in the Company on a fully-diluted basis at December 31, 2017. Borrowings may be made by the Company through December 31, 2018. Borrowings bear interest at the Applicable Federal Rate for short term loans published by the Internal Revenue Service (1.51% on December 19, 2017). All borrowings and interest are due on December 31, 2019 but may be prepaid without penalty. In connection with the Line of Credit agreement, the Company issued to Mr. Uihlein warrants to purchase 1 million shares of the Company’s common stock for $5 per share. Half of the warrants vested at closing of the Line of Credit and the other half vest ratably with borrowings under the agreement. There have been no borrowings under the Line of Credit through March 31, 2018.   The fair value of the 500,000 warrants vested at closing was $696,000 at the date of issuance based on the following assumptions: an expected life of 7 years, volatility of 98%, risk free interest rate of 2.05% and zero dividends. The fair value of the vested warrants was recorded in other current assets and other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from December 19, 2017 through December 31, 2019. Amortization for the three months ended March 31, 2018 of $84,000 was recorded as interest expense. The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through December 31, 2019. </div>

2018-03-31 Smaller Reporting Company

<div> The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2017 through March 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,155,263</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.11</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">460,000</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.87</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Options forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,615,263</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

<div> The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.18</td> <td valign="bottom" nowrap="nowrap">%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected life of the options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5 years</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility of the underlying stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">103</td> <td valign="bottom" nowrap="nowrap">%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected dividend rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">%</td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> The following table summarizes the common stock warrant activity from December 31, 2017 through March 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,229,778</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.35</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">163</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.23</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,780,478</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.50</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,449,463</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

460000

115000

<div> 8. Common Stock 2014 At Market Issuance of Common Stock On March 30, 2014, the Company entered into an At Market Issuance Sales Agreement (the “2014 At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $30.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the 2014 At Market Agreement. In three months ended March 31, 2017, the Company issued 1,496,797 shares of common stock for net proceeds of approximately $1,945,000 under the 2014 At Market Agreement. The 2014 At Market Agreement expired in March 2017.   2017 At Market Issuance of Common Stock On May 19, 2017, the Company entered into an At Market Issuance Sales Agreement (the “2017 At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $30.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the 2017 At Market Agreement. During the three months ended March 31, 2018, there were no issuances of common stock under the 2017 At Market Agreement. 2017 Private Placement On February 28, 2017, the Company closed a transaction with five individual investors through a private placement of common stock and warrants. In total, the Company issued 102,368 shares of common stock for proceeds of $200,000. The Company also issued, to the five investors, warrants to purchase 76,776 shares of common stock at $5.00 per share. The warrants have an expiration date of February 28, 2024. The exercise price of each warrant is adjustable in the event of a stock split or stock combination, capital reorganization, merger or similar event. The warrants were valued at approximately $101,000 as of the date of issuance, using the closing price of $1.86, a life of 7 years, a volatility of 97% and a risk free interest rate of 1.92%. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity” the Company has determined that warrants issued in connection with this financing transaction were not derivative liabilities and therefore, were recorded as additional paid-in capital. Other In 2018, the Company entered an agreement with a vendor whereby the Company will issue common stock to vendor in lieu of paying in cash in amount up to $100,000 for the year. For the three months ended March 31, 2018, the Company has issued 1,629 shares of common stock and 163 warrants to purchase shares of common stock pursuant to this agreement and the value of such shares has been recorded as research and development expense. For the three months ended March 31, 2018, the Company has issued a total of 74,476 shares of common stock for dividends on Series A, Series B and Series C Preferred Stock. </div>

-0.12

<div> 7. Loss Per Share Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share. Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018 (shares)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017 (shares)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Warrants to purchase shares of common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,449,463</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,249,016</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Options to purchase shares of common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,615,263</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,656,888</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Shares of common stock issuable upon conversion of preferred stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,312,282</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,312,282</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,377,008</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,218,186</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P9M

GALECTIN THERAPEUTICS INC

<div> 6. Fair Value of Financial Instruments The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximate their carrying value due to their short-term nature. There were no level 2 or level 3 assets or liabilities at March 31, 2018 or December 31, 2017. </div>

<div> Accrued expenses consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Legal and accounting fees </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued compensation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">314</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">790</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued research and development costs and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">767</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,428</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,132</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,292</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1.03

-4178000

-4258000

4000

-80000

-4543000

-81000

84000

7000

285000

4451000

1187000

84000

1880000

84000

4451000

2298000

935000

-617000

4178000

<div> 5. Common Stock Warrants The following table summarizes the common stock warrant activity from December 31, 2017 through March 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,229,778</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.35</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">163</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.23</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,780,478</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.50</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding, March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,449,463</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div> 767000 696000 353000

526000

0.798

163

74476

23000

P7Y

0.00

0.0205

0.98

1780478

163

0 2.50 5.23

345000

4312282

5615263

11449463

2024-02-28

653000

534000

0001133416 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001133416 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001133416 galt:PrivatePlacementTwentySeventeenMember 2018-01-01 2018-03-31 0001133416 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001133416 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001133416 us-gaap:StockCompensationPlanMember 2018-01-01 2018-03-31 0001133416 galt:RemainderOfCurrentYearMember 2018-01-01 2018-03-31 0001133416 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001133416 galt:GalectinSciencesLlcMember 2018-01-01 2018-03-31 0001133416 galt:TwoThousandSeventeenAtMarketSalesAgreementMember 2018-01-01 2018-03-31 0001133416 galt:SeriesAndPreferredStockMembergalt:OtherAgreementsMember 2018-01-01 2018-03-31 0001133416 galt:OtherAgreementsMember 2018-01-01 2018-03-31 0001133416 galt:GalectinSciencesLlcMembergalt:SbhSciencesIncMember 2018-01-01 2018-03-31 0001133416 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001133416 2018-01-01 2018-03-31 0001133416 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001133416 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0001133416 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001133416 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001133416 us-gaap:StockCompensationPlanMember 2017-01-01 2017-03-31 0001133416 galt:TwoThousandFourteenAtMarketSalesAgreementMember 2017-01-01 2017-03-31 0001133416 2017-01-01 2017-03-31 0001133416 2017-01-01 2017-12-31 0001133416 galt:GalectinSciencesLlcMember 2014-01-01 2014-01-31 0001133416 galt:GalectinSciencesLlcMember 2015-01-01 2018-03-31 0001133416 galt:GalectinSciencesLlcMembergalt:SbhSciencesIncMember 2015-01-01 2018-03-31 0001133416 galt:PrivatePlacementTwentySeventeenMember 2017-02-28 2017-02-28 0001133416 us-gaap:DirectorMember 2017-12-31 0001133416 us-gaap:WarrantMember 2017-12-31 0001133416 galt:SeriesBTwoConvertiblePreferredStockMember 2017-12-31 0001133416 galt:SeriesBOneConvertiblePreferredStockMember 2017-12-31 0001133416 galt:SeriesAConvertiblePreferredStockMember 2017-12-31 0001133416 galt:SeriesBThreeConvertiblePreferredStockMember 2017-12-31 0001133416 us-gaap:SeriesCPreferredStockMember 2017-12-31 0001133416 2017-12-31 0001133416 2016-12-31 0001133416 us-gaap:WarrantMember 2018-03-31 0001133416 galt:SeriesBTwoConvertiblePreferredStockMember 2018-03-31 0001133416 galt:SeriesBOneConvertiblePreferredStockMember 2018-03-31 0001133416 galt:SeriesAConvertiblePreferredStockMember 2018-03-31 0001133416 galt:SeriesBThreeConvertiblePreferredStockMember 2018-03-31 0001133416 us-gaap:SeriesCPreferredStockMember 2018-03-31 0001133416 galt:GalectinSciencesLlcMember 2018-03-31 0001133416 us-gaap:MaximumMembergalt:VendorMembergalt:OtherAgreementsMember 2018-03-31 0001133416 galt:VendorMembergalt:OtherAgreementsMember 2018-03-31 0001133416 galt:UnsecuredLineOfCreditMemberus-gaap:DirectorMember 2018-03-31 0001133416 2018-03-31 0001133416 2017-03-31 0001133416 galt:TwoThousandFourteenAtMarketSalesAgreementMember 2014-03-30 0001133416 2018-05-08 0001133416 galt:UnsecuredLineOfCreditMemberus-gaap:DirectorMember 2017-12-19 0001133416 galt:TwoThousandSeventeenAtMarketSalesAgreementMember 2017-05-19 0001133416 galt:PrivatePlacementTwentySeventeenMember 2017-02-28 0001133416 galt:GalectinSciencesLlcMember 2014-01-31 0001133416 galt:GalectinSciencesLlcMembergalt:SbhSciencesIncMemberus-gaap:InProcessResearchAndDevelopmentMember 2014-01-31 iso4217:USD pure iso4217:USD shares shares

EX-101.SCH 7 galt-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Line of Credit link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Common Stock Warrants link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Loss Per Share link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Common Stock link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Galectin Sciences LLC link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Common Stock Warrants (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Line of Credit - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Stock-Based Compensation Expense Related to Common Stock Options, Restricted Common Stock and Common Stock Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Common Stock Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Common Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Galectin Science LLC - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 galt-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 galt-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 galt-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Accrued Professional Fees, Current Legal and accounting fees Accrued Research and Development Costs and Other Accrued Research and Development Costs and Other Accrued research and development costs and other Additional Paid in Capital Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Aggregate offering price. Aggregate Offering Price Aggregate offering price Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Dilutive shares not included in calculation Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Award Type [Axis] Award Type [Axis] Basis of Accounting [Text Block] Basis of Presentation Basis of Presentation [Line Items] Basis of Presentation [Line Items] Basis of Presentation [Line Items] Basis of Presentation [Table] Basis of Presentation [Table] Basis of Presentation [Table] Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, END OF PERIOD CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD Cash and cash equivalents Unrestricted cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] NONCASH FINANCING ACTIVITIES: Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrant Issuance of warrants, price per share Class of warrant or right issued in period. Class of Warrant or Right, Issued in Period Warrants issued Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of securities called by warrant Commissions as percentage of gross offering proceeds. Commissions as Percentage of Gross Offering Proceeds Commission to sales agent as a percentage of gross proceeds Commitments and Contingencies Commitments and contingencies (Note 9) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock Dividends, Shares Common Stock issued for dividend Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, issued Common Stock, Shares, Issued Common Stock, Shares, Outstanding Common stock, outstanding Common Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2018 and December 31, 2017, 37,645,971 and 35,789,388 issued and outstanding at March 31, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Counterparty Name [Axis] Counterparty Name [Axis] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Line of Credit Debt Instrument, Interest Rate, Stated Percentage Short term borrowing interest rate Depreciation, Depletion and Amortization Depreciation and amortization Director [Member] Director Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Dividends Payable, Current Accrued dividends payable Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Net loss per common share - basic and diluted Earnings Per Share [Text Block] Loss Per Share Employee-related Liabilities, Current Accrued compensation Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, recognition period Employee Stock Option [Member] Stock Options Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Equity Interest Type [Axis] Equity Interest Type [Axis] Equity Interest Issued or Issuable, Type [Domain] Equity Interest Issued or Issuable, Type [Domain] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Fair Value Assumptions, Expected Term Fair value assumptions, term of warrants Fair Value Assumptions, Expected Volatility Rate Warrants, volatility rate Fair Value Assumptions, Risk Free Interest Rate Warrants , risk free interest rate Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Fair Value Of Asset Contributed To Joint Venture Fair Value Of Asset Contributed To Joint Venture Estimated fair value of the IPR&D Contributed by SBH Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Galectin Sciences, LLC [Member] Galectin Sciences, LLC [Member] Galectin Sciences, LLC General and Administrative Expense General and administrative General and Administrative Expense [Member] General and administrative Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets In Process Research and Development [Member] In Process Research and Development Interest Expense Interest expense Interest Expense, Debt Amortization of interest expense Investment Income, Interest Interest income Investments in and Advances to Affiliates [Abstract] Investments in and Advances to Affiliates [Abstract] Investments in and Advances to Affiliates [Line Items] Investments in and Advances to Affiliates [Line Items] Investments in and Advances to Affiliates, Schedule of Investments [Text Block] Galectin Sciences LLC Investments in and Advances to Affiliates [Table] Investments in and Advances to Affiliates [Table] Issuance of Stock and Warrants for Services or Claims Issuance of common stock for services Issuance Of Warrants, Value Issuance Of Warrants, Value Warrant value Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities and Equity Total liabilities, redeemable convertible preferred stock and stockholders' equity(deficit) Liabilities and Equity [Abstract] LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Line of Credit Facility [Abstract] Line of Credit Facility [Abstract] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Line of credit facility Line of Credit Facility [Table] Line of Credit Facility [Table] Line of Credit, Current Line of credit current Maximum [Member] Maximum Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Minority interest Noncontrolling Interest, Ownership Percentage by Parent Equity Method Investment, Ownership Percentage Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss) Attributable to Parent Net loss Net loss Net Income (Loss) Available to Common Stockholders, Basic Net loss applicable to common stockholders Nonoperating Income (Expense) Total other income (expense) Nonoperating Income (Expense) [Abstract] Other income (expense): Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Total operating loss Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other Agreements [Member] Other Agreements [Member] Other Agreements Other Assets, Noncurrent Other Paid-in-Kind Interest Non-cash interest expense Payables and Accruals [Abstract] Payables and Accruals [Abstract] Payments to Acquire Businesses and Interest in Affiliates Subsequent capital contribution Payments to Acquire Equity Method Investments Equity method investment in Galectin Sciences LLC Preferred Stock Dividends, Income Statement Impact Preferred stock dividends Preferred Stock, Liquidation Preference, Value Convertible preferred stock, liquidation value Preferred Stock, Shares Authorized Convertible preferred stock, shares authorized Preferred Stock, Shares Issued Convertible preferred stock, issued Preferred Stock, Shares Outstanding Convertible preferred stock, outstanding Preferred Stock, Value, Issued Convertible preferred stock, value Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Private Placement Twenty Seventeen Member. Private Placement Twenty Seventeen [Member] Private Placement 2017 Proceeds from Issuance of Common Stock Net proceeds from issuance of common stock Net proceeds from issuance of common stock and warrants Proceeds from Issuance of Private Placement Proceeds from sale of common stock Range [Axis] Range [Axis] Range [Domain] Range [Domain] Related Party [Domain] Related Party [Domain] Related Party [Axis] Related Party [Axis] Remainder Of Current Year [Member] Remainder Of Current Year [Member] Remainder Of 2018 Counterparty Name [Domain] Counterparty Name [Domain] Research and Development Expense Research and development Research and Development Expense [Member] Research and development Retained Earnings (Accumulated Deficit) Retained deficit SBH Sciences, Inc [Member] SBH Sciences, Inc [Member] SBH Sciences, Inc Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table Text Block] Accrued Expenses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Stock-Based Compensation Expense Related to Common Stock Options, Restricted Common Stock and Common Stock Warrants Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Stock Option Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Weighted Average Assumptions Used to Determine Fair Value of Options Granted Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock Warrant Activity Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series A 12% convertible preferred stock Series A, B and C Preferred Stock [Member] Series and Preferred Stock [Member] Series A, B and C Preferred Stock Series B One Convertible Preferred Stock [Member] Series B One Convertible Preferred Stock [Member] Series B-1 12% convertible preferred stock Series B Three Convertible Preferred Stock [Member] Series B Three Convertible Preferred Stock [Member] Series B-3 8% convertible preferred stock Series B Two Convertible Preferred Stock [Member] Series B Two Convertible Preferred Stock [Member] Series B-2 12% convertible preferred stock Series C Preferred Stock [Member] Series C super dividend convertible preferred stock Share-based Compensation Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited/cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited/cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Outstanding, March 31, 2018 Outstanding, December 31, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Exercise Price Outstanding, March 31, 2018 Outstanding, December 31, 2017 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend Expected dividend rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life Expected life of the options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected Volatility Expected volatility of the underlying stock Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options forfeited/cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Number of options granted EX-101.PRE 11 galt-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 08, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Trading Symbol	GALT
Entity Registrant Name	GALECTIN THERAPEUTICS INC
Entity Central Index Key	0001133416
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		37,740,647

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 3,988	$ 3,053
Prepaid expenses and other current assets	685	766
Total current assets	4,673	3,819
Other	258	342
Total assets	4,931	4,161
Current liabilities:
Accounts payable	1,151	608
Accrued expenses	1,132	2,292
Accrued dividends payable		68
Total current liabilities	2,283	2,968
Total liabilities	2,283	2,968
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at March 31, 2018 and December 31, 2017, respectively	0	0
Common stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2018 and December 31, 2017, 37,645,971 and 35,789,388 issued and outstanding at March 31, 2018 and December 31, 2017, respectively	38	36
Additional paid-in capital	179,359	173,363
Retained deficit	(185,711)	(181,168)
Total stockholders' equity(deficit)	925	(530)
Total liabilities, redeemable convertible preferred stock and stockholders' equity(deficit)	4,931	4,161
Series C super dividend convertible preferred stock
Current liabilities:
Convertible preferred stock, value	1,723	1,723
Series A 12% convertible preferred stock
Stockholders' equity (deficit):
Convertible preferred stock, value	557	557
Series B-1 12% convertible preferred stock
Stockholders' equity (deficit):
Convertible preferred stock, value	1,761	1,761
Series B-2 12% convertible preferred stock
Stockholders' equity (deficit):
Convertible preferred stock, value	3,697	3,697
Series B-3 8% convertible preferred stock
Stockholders' equity (deficit):
Convertible preferred stock, value	$ 1,224	$ 1,224

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Undesignated stock, par value	$ 0.01	$ 0.01
Undesignated stock, shares authorized	20,000,000	20,000,000
Undesignated stock, shares designated	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, issued	37,645,971	35,789,388
Common stock, outstanding	37,645,971	35,789,388
Series C super dividend convertible preferred stock
Convertible preferred stock, shares authorized	1,000	1,000
Convertible preferred stock, shares issued	176	176
Convertible preferred stock, shares outstanding	176	176
Convertible preferred stock, redemption value	$ 7,957,000
Convertible preferred stock, liquidation value	$ 1,760,000
Series A 12% convertible preferred stock
Convertible preferred stock, shares authorized	1,742,500	1,742,500
Convertible preferred stock, issued	1,377,500	1,377,500
Convertible preferred stock, outstanding	1,377,500	1,377,500
Convertible preferred stock, liquidation value	$ 1,377,500
Series B-1 12% convertible preferred stock
Convertible preferred stock, shares authorized	900,000	900,000
Convertible preferred stock, issued	900,000	900,000
Convertible preferred stock, outstanding	900,000	900,000
Convertible preferred stock, liquidation value	$ 1,800,000
Series B-2 12% convertible preferred stock
Convertible preferred stock, shares authorized	2,100,000	2,100,000
Convertible preferred stock, issued	2,100,000	2,100,000
Convertible preferred stock, outstanding	2,100,000	2,100,000
Convertible preferred stock, liquidation value	$ 4,200,000
Series B-3 8% convertible preferred stock
Convertible preferred stock, shares authorized	2,508,000	2,508,000
Convertible preferred stock, issued	2,508,000	2,508,000
Convertible preferred stock, outstanding	2,508,000	2,508,000
Convertible preferred stock, liquidation value	$ 2,508,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating expenses:
Research and development	$ 2,298	$ 3,772
General and administrative	1,880	1,174
Total operating expenses	4,178	4,946
Total operating loss	(4,178)	(4,946)
Other income (expense):
Interest income	4	9
Interest expense	(84)
Total other income (expense)	(80)	9
Net loss	(4,258)	(4,937)
Preferred stock dividends	(285)	(272)
Net loss applicable to common stockholders	$ (4,543)	$ (5,209)
Net loss per common share - basic and diluted	$ (0.12)	$ (0.15)
Weighted average common shares outstanding - basic and diluted	37,284	33,928

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,258)	$ (4,937)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1
Stock-based compensation expense	1,187	330
Issuance of common stock for services	7	14
Non-cash interest expense	84
Changes in operating assets and liabilities:
Prepaid expenses and other assets	81	79
Accounts payable and accrued expenses	(617)	650
Net cash used in operating activities	(3,516)	(3,863)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants	4,451	2,145
Net cash provided by financing activities	4,451	2,145
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	935	(1,718)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	3,053	15,362
CASH AND CASH EQUIVALENTS, END OF PERIOD	3,988	13,644
NONCASH FINANCING ACTIVITIES:
Payment of preferred stock dividends in common stock	$ 353	$ 339

XML 17 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Mar. 31, 2018

Basis of Presentation

1. Basis of Presentation

XML 18 R7.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2018

Accrued Expenses

2. Accrued Expenses

Accrued expenses consist of the following:


	March 31, 2018		December 31, 2017
	(in thousands)
Legal and accounting fees	$	51	$	74
Accrued compensation		314		790
Accrued research and development costs and other		767		1,428

Total	$	1,132	$	2,292

XML 19 R8.htm IDEA: XBRL DOCUMENT

Line of Credit

3 Months Ended

Mar. 31, 2018

Line of Credit

3. Line of Credit

XML 20 R9.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2018

Stock-Based Compensation

4. Stock-Based Compensation

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:


	Three Months Ended March 31,
	2018		2017
Research and development	$	534	$	166
General and administrative		653		164

Total stock-based compensation expense	$	1,187	$	330

The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2017 through March 31, 2018:


	Shares		Weighted Average Exercise Price
Outstanding, December 31, 2017		5,155,263	$	4.11
Granted		460,000		5.87
Exercised		—		—
Options forfeited/cancelled		—		—

Outstanding, March 31, 2018		5,615,263	$	4.26

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:


	Three Months Ended March 31,			Three Months Ended March 31,
	2018			2017
Risk-free interest rate		2.18	%		—
Expected life of the options		5 years			—
Expected volatility of the underlying stock		103	%		—
Expected dividend rate		0	%		—

XML 21 R10.htm IDEA: XBRL DOCUMENT

Common Stock Warrants

3 Months Ended

Mar. 31, 2018

Common Stock Warrants

5. Common Stock Warrants

The following table summarizes the common stock warrant activity from December 31, 2017 through March 31, 2018:


	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2017		13,229,778		$	3.35
Granted		163			5.23
Exercised		(1,780,478	)		2.50
Forfeited/cancelled		—			—

Outstanding, March 31, 2018		11,449,463		$	3.48

XML 22 R11.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2018

Fair Value of Financial Instruments

6. Fair Value of Financial Instruments

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Loss Per Share

3 Months Ended

Mar. 31, 2018

Loss Per Share

7. Loss Per Share


	March 31, 2018 (shares)		March 31, 2017 (shares)
Warrants to purchase shares of common stock		11,449,463		12,249,016
Options to purchase shares of common stock		5,615,263		4,656,888
Shares of common stock issuable upon conversion of preferred stock		4,312,282		4,312,282

		21,377,008		21,218,186

XML 24 R13.htm IDEA: XBRL DOCUMENT

Common Stock

3 Months Ended

Mar. 31, 2018

Common Stock

8. Common Stock

2014 At Market Issuance of Common Stock

2017 At Market Issuance of Common Stock

2017 Private Placement

Other

For the three months ended March 31, 2018, the Company has issued a total of 74,476 shares of common stock for dividends on Series A, Series B and Series C Preferred Stock.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies

9. Commitments and Contingencies

Shareholder Class Actions and Derivative Lawsuits

Other Legal Proceedings

XML 26 R15.htm IDEA: XBRL DOCUMENT

Galectin Sciences LLC

3 Months Ended

Mar. 31, 2018

Galectin Sciences LLC

10. Galectin Sciences LLC

XML 27 R16.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2018

Accrued Expenses

Accrued expenses consist of the following:


	March 31, 2018		December 31, 2017
	(in thousands)
Legal and accounting fees	$	51	$	74
Accrued compensation		314		790
Accrued research and development costs and other		767		1,428

Total	$	1,132	$	2,292

XML 28 R17.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2018

Stock-Based Compensation Expense Related to Common Stock Options, Restricted Common Stock and Common Stock Warrants

Following is the stock-based compensation expense related to common stock options, common stock, restricted common stock and common stock warrants:


	Three Months Ended March 31,
	2018		2017
Research and development	$	534	$	166
General and administrative		653		164

Total stock-based compensation expense	$	1,187	$	330

Summary of Stock Option Activity

The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2017 through March 31, 2018:


	Shares		Weighted Average Exercise Price
Outstanding, December 31, 2017		5,155,263	$	4.11
Granted		460,000		5.87
Exercised		—		—
Options forfeited/cancelled		—		—

Outstanding, March 31, 2018		5,615,263	$	4.26

Weighted Average Assumptions Used to Determine Fair Value of Options Granted

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:


	Three Months Ended March 31,			Three Months Ended March 31,
	2018			2017
Risk-free interest rate		2.18	%		—
Expected life of the options		5 years			—
Expected volatility of the underlying stock		103	%		—
Expected dividend rate		0	%		—

XML 29 R18.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Tables)

3 Months Ended

Mar. 31, 2018

Common Stock Warrant Activity

The following table summarizes the common stock warrant activity from December 31, 2017 through March 31, 2018:


	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2017		13,229,778		$	3.35
Granted		163			5.23
Exercised		(1,780,478	)		2.50
Forfeited/cancelled		—			—

Outstanding, March 31, 2018		11,449,463		$	3.48

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2018

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation


	March 31, 2018 (shares)		March 31, 2017 (shares)
Warrants to purchase shares of common stock		11,449,463		12,249,016
Options to purchase shares of common stock		5,615,263		4,656,888
Shares of common stock issuable upon conversion of preferred stock		4,312,282		4,312,282

		21,377,008		21,218,186

XML 31 R20.htm IDEA: XBRL DOCUMENT

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Basis of Presentation [Line Items]
Unrestricted cash and cash equivalents	$ 3,988	$ 3,053	$ 13,644	$ 15,362

XML 32 R21.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Schedule of Accrued Liabilities [Line Items]
Legal and accounting fees	$ 51	$ 74
Accrued compensation	314	790
Accrued research and development costs and other	767	1,428
Total	$ 1,132	$ 2,292

XML 33 R22.htm IDEA: XBRL DOCUMENT

Line of Credit - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 19, 2017
Line of Credit Facility [Line Items]
Number of securities called by warrant	500,000
Warrant value	$ 696,000
Expected life	5 years
Expected Volatility	103.00%
Expected dividend	0.00%
Risk free interest rate	2.18%
Amortization of interest expense	$ 84,000
Director
Line of Credit Facility [Line Items]
Minority interest		7.00%
Unsecured Line Of Credit \| Director
Line of Credit Facility [Line Items]
Line of credit facility			$ 10,000,000
Short term borrowing interest rate			1.51%
Number of securities called by warrant	1,000,000
Exercise price of warrant	$ 5
Line of credit current	$ 0
Warrant
Line of Credit Facility [Line Items]
Expected life	7 years
Expected Volatility	98.00%
Expected dividend	0.00%
Risk free interest rate	2.05%

XML 34 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Expense Related to Common Stock Options, Restricted Common Stock and Common Stock Warrants (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,187	$ 330
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	534	166
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 653	$ 164

XML 35 R24.htm IDEA: XBRL DOCUMENT

Summary of Stock Option Activity (Detail)	3 Months Ended
Summary of Stock Option Activity (Detail)	Mar. 31, 2018 $ / shares shares
Shares
Beginning Balance \| shares	5,155,263
Granted \| shares	460,000
Exercised \| shares	0
Options forfeited/cancelled \| shares	0
Ending Balance \| shares	5,615,263
Weighted Average Exercise Price
Beginning Balance \| $ / shares	$ 4.11
Granted \| $ / shares	5.87
Exercised \| $ / shares	0
Options forfeited/cancelled \| $ / shares	0
Ending Balance \| $ / shares	$ 4.26

XML 36 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 1,972,000
Unvested option	951,181
Unrecognized compensation cost, recognition period	9 months
Weighted-average grant-date fair values of options granted	$ 4.57
Number of options granted	460,000
Number of options vested	115,000
Stock-based compensation expense	$ 1,187,000	$ 330,000
Remainder Of 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options vested	345,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 526,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail)	3 Months Ended
	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.18%
Expected life of the options	5 years
Expected volatility of the underlying stock	103.00%
Expected dividend rate	0.00%

XML 38 R27.htm IDEA: XBRL DOCUMENT

Common Stock Warrant Activity (Detail) - Warrant	3 Months Ended
Common Stock Warrant Activity (Detail) - Warrant	Mar. 31, 2018 $ / shares shares
Shares
Outstanding, December 31, 2017 \| shares	13,229,778
Granted \| shares	163
Exercised \| shares	(1,780,478)
Forfeited/cancelled \| shares	0
Outstanding, March 31, 2018 \| shares	11,449,463
Weighted Average Exercise Price
Outstanding, December 31, 2017 \| $ / shares	$ 3.35
Granted \| $ / shares	5.23
Exercised \| $ / shares	2.50
Forfeited/cancelled \| $ / shares	0
Outstanding, March 31, 2018 \| $ / shares	$ 3.48

XML 39 R28.htm IDEA: XBRL DOCUMENT

Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	21,377,008	21,218,186
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	11,449,463	12,249,016
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	5,615,263	4,656,888
Contingently Issuable Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive shares not included in calculation	4,312,282	4,312,282

XML 40 R29.htm IDEA: XBRL DOCUMENT

Common Stock - Additional Information (Detail) - USD ($)		3 Months Ended
	Feb. 28, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	May 19, 2017	Mar. 30, 2014
Class of Stock [Line Items]
Net proceeds from issuance of common stock		$ 4,451,000	$ 2,145,000
Common Stock, Value, Issued		$ 38,000		$ 36,000
Common Stock, Shares, Issued		37,645,971		35,789,388
Private Placement 2017
Class of Stock [Line Items]
Shares of common stock issued	102,368
Proceeds from sale of common stock	$ 200,000
Warrants issued	76,776
Issuance of warrants, price per share	$ 5.00
Issuance of warrants, value	$ 101,000
Issuance of warrants, closing price	$ 1.86
Fair value assumptions, term of warrants	7 years
Warrants, volatility rate	97.00%
Warrants , risk free interest rate	1.92%
Warrants expiration date		Feb. 28, 2024
2014 At Market Agreement
Class of Stock [Line Items]
Aggregate offering price						$ 30,000,000
Commission to sales agent as a percentage of gross proceeds						3.00%
Shares of common stock issued			1,496,797
Net proceeds from issuance of common stock			$ 1,945,000
2017 At Market Agreement
Class of Stock [Line Items]
Aggregate offering price					$ 30,000,000
Commission to sales agent as a percentage of gross proceeds					3.00%
Shares of common stock issued		0
Other Agreements
Class of Stock [Line Items]
Warrants issued		163
Other Agreements \| Series A, B and C Preferred Stock
Class of Stock [Line Items]
Common Stock issued for dividend		74,476
Other Agreements \| Vendor
Class of Stock [Line Items]
Common Stock, Shares, Issued		1,629
Other Agreements \| Maximum \| Vendor
Class of Stock [Line Items]
Common Stock, Value, Issued		$ 100,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Galectin Science LLC - Additional Information (Detail) - Galectin Sciences, LLC - USD ($)	1 Months Ended	3 Months Ended	39 Months Ended
	Jan. 31, 2014	Mar. 31, 2018	Mar. 31, 2018
Investments in and Advances to Affiliates [Line Items]
Equity method investment in Galectin Sciences LLC	$ 400,000
Subsequent capital contribution		$ 23,000	$ 1,663,000
Equity Method Investment, Ownership Percentage	50.00%	79.80%	79.80%
SBH Sciences, Inc
Investments in and Advances to Affiliates [Line Items]
Subsequent capital contribution			$ 123,000
Ownership Percentage		79.80%
SBH Sciences, Inc \| In Process Research and Development
Investments in and Advances to Affiliates [Line Items]
Estimated fair value of the IPR&D Contributed by SBH	$ 400,000

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ⅅ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�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end

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company